Nisa Investment Advisors LLC Has $40.95 Million Stock Holdings in Boston Scientific Corporation (NYSE:BSX)

Nisa Investment Advisors LLC lifted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 405,955 shares of the medical equipment provider's stock after purchasing an additional 17,160 shares during the quarter. Nisa Investment Advisors LLC's holdings in Boston Scientific were worth $40,953,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Axxcess Wealth Management LLC boosted its stake in Boston Scientific by 13.7% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,228 shares of the medical equipment provider's stock valued at $1,032,000 after buying an additional 1,234 shares in the last quarter. Rehmann Capital Advisory Group raised its position in Boston Scientific by 6.1% in the 1st quarter. Rehmann Capital Advisory Group now owns 5,567 shares of the medical equipment provider's stock valued at $562,000 after purchasing an additional 322 shares during the last quarter. Greenleaf Trust raised its position in Boston Scientific by 6.3% in the 1st quarter. Greenleaf Trust now owns 28,258 shares of the medical equipment provider's stock valued at $2,851,000 after purchasing an additional 1,665 shares during the last quarter. Trek Financial LLC raised its position in Boston Scientific by 990.2% in the 1st quarter. Trek Financial LLC now owns 34,504 shares of the medical equipment provider's stock valued at $3,481,000 after purchasing an additional 31,339 shares during the last quarter. Finally, Personal CFO Solutions LLC bought a new position in Boston Scientific in the 1st quarter valued at $219,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president directly owned 18,705 shares of the company's stock, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,347,824.96. This trade represents a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 461,970 shares of company stock valued at $47,755,193 over the last ninety days. Company insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.7%

Shares of Boston Scientific stock traded down $0.70 during trading hours on Friday, hitting $103.16. The company's stock had a trading volume of 5,890,147 shares, compared to its average volume of 6,710,119. Boston Scientific Corporation has a 12 month low of $71.88 and a 12 month high of $107.53. The stock has a 50 day moving average of $103.42 and a 200 day moving average of $100.60. The company has a market capitalization of $152.62 billion, a PE ratio of 75.30, a price-to-earnings-growth ratio of 2.68 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The company's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.56 earnings per share. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Leerink Partners assumed coverage on Boston Scientific in a research report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price objective for the company. Robert W. Baird lifted their price objective on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Truist Financial lifted their price objective on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. BTIG Research restated a "buy" rating and set a $124.00 target price on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Barclays boosted their target price on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Twenty-two research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of "Buy" and a consensus price target of $116.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.